Diet Alone

OTHER3 trials

Sponsors

Mashhad University of Medical Sciences, Sanofi

Conditions

HypercholesterolemiaNon Alcoholic Steatohepatitis. Diseases of liver

Phase 3

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

CompletedNCT02023879

SanofiHypercholesterolemia

Start: 2013-12-16End: 2017-06-30Updated: 2018-07-27

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

CompletedNCT02584504

SanofiHypercholesterolemia

Start: 2015-11-30End: 2018-01-09Updated: 2019-01-23

Unknown Phase

The Effect of Exercise and nutrition on fatty liver disease

Active, not recruitingIRCT201104286319N1

Mashhad University of Medical SciencesNon Alcoholic Steatohepatitis. Diseases of liver

Start: 2010-04-04Target: 30Updated: 2018-02-22

Related Papers

Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.

2018-11-3015 citations

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.

2017-06-179 citations

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Journal of the American Heart Association2016-09-01100 citations

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Journal of the American Heart Association2016-06-1142 citations